Literature DB >> 10801148

Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue.

H Ooiwa1, T Miyazawa, Y Yamanishi, K Hiyama, S Ishioka, M Yamakido.   

Abstract

Systemic lupus erythematosus (SLE) is sometimes reported to complicate fatal pulmonary hypertension. A 46-year-old woman, with a ten-year history of SLE and pulmonary hypertension, was admitted to our hospital complaining of dyspnea and chest pain. She suffered pulmonary hemorrhage and after steroid pulse therapy, she underwent continuous intravenous infusion of epoprostenol (prostaglandin I2) with corticosteroid for four weeks, which reduced the pulmonary artery pressure and resistance. Following the successful treatment, beraprost sodium, an oral PGI2 analogue, was given and it maintained pulmonary hypertension remittance for four years.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801148     DOI: 10.2169/internalmedicine.39.320

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus.

Authors:  Yoshihiro Matsukawa; Kohmei Igei; Takamasa Nozaki; Takafumi Ohki; Takako Shimizu; Noboru Kitamura; Ko Mitamura; Masami Takei; Yuji Kasamaki; Shigemasa Sawada
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

2.  Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.

Authors:  Ismail Hanta; Mesut Demir; Onur Akpinar; Ali Kocabas; Suleyman Ozbek
Journal:  Clin Rheumatol       Date:  2005-06-11       Impact factor: 2.980

3.  Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension.

Authors:  Son-Mi Chung; Chang-Keun Lee; Eun Young Lee; Bin Yoo; Sang-Do Lee; Hee-Bom Moon
Journal:  Clin Rheumatol       Date:  2006-02-22       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.